Bacteria that live in and on our bodies outnumber the number of human cells by 10 to one.
There is an increased awareness that these bacteria, called the microbiome, play a crucial role in human health and diseases.
Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic, gastrointestinal and other diseases.
Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.
Recent studies have demonstrated the involvement of the intestinal microbiota in insulin resistance.
Caelus Health have identified and patented a single species, E. hallii, which through preclinical studies has proven to be capable of reducing insulin resistance, a primary symptom of type 2 diabetes.
Caelus’ lead strain, CP-001, is a formulation of E. hallii and is currently in phase I clinical study.
